KA/EN
Register
Medicines reference
Search
Search
Active substance

Enoxaparin

Favourites

Low molecular weight heparin. Registered in Georgia: 1 human medicine. Forms: solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Enoxaparin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
1 mg/kg
off-label
 Cat Arterial Thromboembolism Subcutaneous once daily
PMC review 2026
Scientific article
A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied.
Treatment and Prevention of Cardiogenic Arterial Thromboembolism in the Cat: A Systematic Review
PMC, 2026
1.78–3.5 mg/kg
off-label
 Cat Arterial Thromboembolism
Emergency
 Subcutaneous every 8-12 hours
PMC review 2026
Scientific article
A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied.
Treatment and Prevention of Cardiogenic Arterial Thromboembolism in the Cat: A Systematic Review
PMC, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Use with caution in a bleeding disorder or during existing antiplatelet treatment. The combination is used intentionally and can be effective in cats, but the bleeding risks are additive.

Known Drug Interactions

  • Major warning Methimazole + Enoxaparin
    Anticoagulants may be potentiated anti-vitamin K activity
    Recommendation: Monitor for signs of bleeding.
    Sources: FDA
Latin name
Enoxaparin
Georgian name
ენოქსაპარინი
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
1 of 1 forms
Products
Clexane
Human medicines in Georgia
Clexane, Cnoxane, Enox, Exopine, Hemoxa, Klexiparin, Neoparin Multi, Parinox, Thrombenox-40, Thrombenox-60, Venaperta
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Clexane 4000 IU (40 mg)/0.4 ml, Solution

solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Subcutaneous anticoagulation for a dog with a defined high-risk or established thrombotic indication, selected by thrombus type and concurrent disease
6.2/10
Situational / acceptable
vetman assessment

Clexane

4000 IU (40 mg)/0.4 ml, solution for injection, human medicine
Assessed clinical scopeDog · Subcutaneous anticoagulation for a dog with a defined high-risk or established thrombotic indication, selected by thrombus type and concurrent disease · Subcutaneous
Care settingVeterinary hospital treatment or exceptionally trained home administration after a defined indication, with dose-accurate sterile preparation and bleeding/renal/platelet review.
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-041732 · Verified on 15 Oct 2026 Off-label use

A credible but outcome-limited canine anticoagulant whose exact 40 mg syringe is poorly suited to most weight-based partial doses and frequent administration.

Regulatory and scientific credibility7.5/10

Exact concentration, device, current Georgian and major-market human authorisations and a detailed current SPC are traceable, with applicable veterinary consensus/species evidence; there is no veterinary authorisation and no exact-product target-animal regulatory dossier.

Clinical efficacy6.0/10

CURATIVE and canine PK/PD support anticoagulant activity at 0.8 mg/kg q6h, but target attainment varies, clinical outcome trials are sparse and superiority over other anticoagulant protocols is unproved.

Safety and tolerability6.5/10

Exact-label haemorrhage, platelet, renal and interaction risks are mature and canine use is generally tolerated, but individual exposure varies and clinical target-animal safety cohorts are limited.

Clinical practicality4.0/10

SC q6h is workable in hospital but staff-intensive; the exact ungraduated single-use 40 mg syringe supplies a whole 0.4 ml dose only to a 50 kg dog at 0.8 mg/kg and cannot itself measure most partial doses accurately.

Full-course cost-effectiveness-

Current exact Georgian pack price, pack count and patient-specific course were not verified; single-use ungraduated-syringe wastage and alternative preparation/device costs are therefore excluded.

Important safety and use flags

  • Human biological medicine. Georgian/EU/GB/US human authorisations do not establish veterinary approval; all assessed dog/cat uses are off-label.
  • 4,000 IU anti-Xa equals 40 mg in 0.4 ml, or 100 mg/ml. Never enter 4,000 as mg/ml: that creates a forty-fold volume error.
  • The exact 40 mg/0.4 ml pre-filled syringe is ungraduated and single-use. It cannot itself measure most dog/cat partial doses accurately; do not present a calculator volume as directly readable from this device.
  • Never administer intramuscularly. Avoid active clinically important bleeding, major haemorrhage-prone lesions and recent high-risk brain, spinal or ophthalmic surgery.
  • Review PCV/haemoglobin, platelet count, renal function, perfusion, potassium risk and injection/line sites. aPTT and ACT do not reliably quantify enoxaparin intensity; consider anti-Xa testing when it can change management.
  • Renal impairment can increase exposure and bleeding. Acute feline ATE also carries substantial AKI risk; reassess dose, interval and continuation as renal function changes.
  • Other anticoagulants, thrombolytics, clopidogrel/aspirin and NSAIDs add haemorrhage risk. Combination treatment may be intentional, but requires a documented indication, monitoring plan and procedural timing.
  • Plan surgery, dentistry, neuraxial/spinal procedures and catheter placement/removal around anticoagulant effect. Unexpected neurologic deficit, painful swelling or persistent bleeding is an emergency.
  • LMWHs are biological products. Record exact trade name and batch; do not substitute another LMWH or heparin product unit-for-unit without a new protocol.
  • Use only clear colourless-to-yellow solution, do not mix in the same syringe/line without verified compatibility, maintain asepsis and discard unused single-use contents. Protamine does not guarantee complete reversal.
Assessment sources
  1. Clexane current SPC2026
  2. GE Clexane audit2026
  3. CURATIVE small animal2019
  4. Canine enoxaparin PK/PD2022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Hospital intravenous bolus plus continuous-rate enoxaparin infusion with clopidogrel for acute feline arterial thromboembolism
5.9/10
Weak evidence support
vetman assessment

Clexane

4000 IU (40 mg)/0.4 ml, solution for injection, human medicine
Assessed clinical scopeCat · Hospital intravenous bolus plus continuous-rate enoxaparin infusion with clopidogrel for acute feline arterial thromboembolism · Intravenous
Care settingIntensive hospital care with calculated dilution, infusion pump, dedicated venous access, anti-Xa/renal/perfusion/bleeding monitoring and full multimodal ATE support.
vetman score 5.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-041732 · Verified on 15 Oct 2026 Off-label use

A direct but uncontrolled feline IV-CRI option for intensive acute ATE care; plausible and monitorable, not yet a comparative standard.

Regulatory and scientific credibility7.0/10

Exact concentration, device, current Georgian and major-market human authorisations and a detailed current SPC are traceable, with applicable veterinary consensus/species evidence; there is no veterinary authorisation and no exact-product target-animal regulatory dossier.

Clinical efficacy6.0/10

A direct 36-cat cohort associated target-range anti-Xa exposure with reperfusion, but the uncontrolled multimodal design cannot establish causality or superiority over SC LMWH, UFH or oral Xa-inhibitor strategies.

Safety and tolerability5.5/10

Bleeding occurred in 6% of the 36-cat cohort, while AKI occurred in 42% in a severely ill population; intensive renal, perfusion, haematologic and anti-Xa oversight is integral to safe use.

Clinical practicality4.5/10

A pump-based CRI is feasible for an intensive-care cat, but exact dilution, small-volume preparation, venous access, continuous infusion, sampling and close monitoring create substantial resource and error-control demands.

Full-course cost-effectiveness-

Current exact Georgian pack price, pack count and patient-specific course were not verified; single-use ungraduated-syringe wastage and alternative preparation/device costs are therefore excluded.

Important safety and use flags

  • Human biological medicine. Georgian/EU/GB/US human authorisations do not establish veterinary approval; all assessed dog/cat uses are off-label.
  • 4,000 IU anti-Xa equals 40 mg in 0.4 ml, or 100 mg/ml. Never enter 4,000 as mg/ml: that creates a forty-fold volume error.
  • The exact 40 mg/0.4 ml pre-filled syringe is ungraduated and single-use. It cannot itself measure most dog/cat partial doses accurately; do not present a calculator volume as directly readable from this device.
  • Never administer intramuscularly. Avoid active clinically important bleeding, major haemorrhage-prone lesions and recent high-risk brain, spinal or ophthalmic surgery.
  • Review PCV/haemoglobin, platelet count, renal function, perfusion, potassium risk and injection/line sites. aPTT and ACT do not reliably quantify enoxaparin intensity; consider anti-Xa testing when it can change management.
  • Renal impairment can increase exposure and bleeding. Acute feline ATE also carries substantial AKI risk; reassess dose, interval and continuation as renal function changes.
  • Other anticoagulants, thrombolytics, clopidogrel/aspirin and NSAIDs add haemorrhage risk. Combination treatment may be intentional, but requires a documented indication, monitoring plan and procedural timing.
  • Plan surgery, dentistry, neuraxial/spinal procedures and catheter placement/removal around anticoagulant effect. Unexpected neurologic deficit, painful swelling or persistent bleeding is an emergency.
  • LMWHs are biological products. Record exact trade name and batch; do not substitute another LMWH or heparin product unit-for-unit without a new protocol.
  • Use only clear colourless-to-yellow solution, do not mix in the same syringe/line without verified compatibility, maintain asepsis and discard unused single-use contents. Protamine does not guarantee complete reversal.
Assessment sources
  1. Clexane current SPC2026
  2. GE Clexane audit2026
  3. CURATIVE small animal2019
  4. Feline enoxaparin CRI2022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Subcutaneous anticoagulation for selected acute or high-risk feline thromboembolic disease; frequent CURATIVE treatment and preliminary q24h dual-therapy contexts remain distinct
6.1/10
Situational / acceptable
vetman assessment

Clexane

4000 IU (40 mg)/0.4 ml, solution for injection, human medicine
Assessed clinical scopeCat · Subcutaneous anticoagulation for selected acute or high-risk feline thromboembolic disease; frequent CURATIVE treatment and preliminary q24h dual-therapy contexts remain distinct · Subcutaneous
Care settingUsually hospital initiation and repeated SC treatment with a validated small-volume preparation/device, explicit interval/endpoint and bleeding, renal and combination-therapy monitoring.
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-041732 · Verified on 15 Oct 2026 Off-label use

Feline PK and consensus support frequent SC enoxaparin, but clinical outcomes are limited and the exact ungraduated 0.4 ml syringe is a serious small-dose mismatch.

Regulatory and scientific credibility7.5/10

Exact concentration, device, current Georgian and major-market human authorisations and a detailed current SPC are traceable, with applicable veterinary consensus/species evidence; there is no veterinary authorisation and no exact-product target-animal regulatory dossier.

Clinical efficacy6.5/10

Direct feline PK/PD and consensus support frequent SC dosing, but human-derived anti-Xa targets, q6-versus-q12 equivalence and clinical outcomes remain uncertain; q24h dual-therapy evidence is small and preliminary.

Safety and tolerability6.5/10

Repeated SC dosing was tolerated in small healthy-cat studies, but bleeding, renal accumulation, injection burden and combination-therapy safety are incompletely quantified in ill cats.

Clinical practicality2.5/10

Typical cat doses are about 0.03–0.10 ml and repeated q6–12h, far below accurate measurement on the exact ungraduated single-use 0.4 ml syringe; validated small-volume preparation and substantial restraint/staff time are required.

Full-course cost-effectiveness-

Current exact Georgian pack price, pack count and patient-specific course were not verified; single-use ungraduated-syringe wastage and alternative preparation/device costs are therefore excluded.

Important safety and use flags

  • Human biological medicine. Georgian/EU/GB/US human authorisations do not establish veterinary approval; all assessed dog/cat uses are off-label.
  • 4,000 IU anti-Xa equals 40 mg in 0.4 ml, or 100 mg/ml. Never enter 4,000 as mg/ml: that creates a forty-fold volume error.
  • The exact 40 mg/0.4 ml pre-filled syringe is ungraduated and single-use. It cannot itself measure most dog/cat partial doses accurately; do not present a calculator volume as directly readable from this device.
  • Never administer intramuscularly. Avoid active clinically important bleeding, major haemorrhage-prone lesions and recent high-risk brain, spinal or ophthalmic surgery.
  • Review PCV/haemoglobin, platelet count, renal function, perfusion, potassium risk and injection/line sites. aPTT and ACT do not reliably quantify enoxaparin intensity; consider anti-Xa testing when it can change management.
  • Renal impairment can increase exposure and bleeding. Acute feline ATE also carries substantial AKI risk; reassess dose, interval and continuation as renal function changes.
  • Other anticoagulants, thrombolytics, clopidogrel/aspirin and NSAIDs add haemorrhage risk. Combination treatment may be intentional, but requires a documented indication, monitoring plan and procedural timing.
  • Plan surgery, dentistry, neuraxial/spinal procedures and catheter placement/removal around anticoagulant effect. Unexpected neurologic deficit, painful swelling or persistent bleeding is an emergency.
  • LMWHs are biological products. Record exact trade name and batch; do not substitute another LMWH or heparin product unit-for-unit without a new protocol.
  • Use only clear colourless-to-yellow solution, do not mix in the same syringe/line without verified compatibility, maintain asepsis and discard unused single-use contents. Protamine does not guarantee complete reversal.
Assessment sources
  1. Clexane current SPC2026
  2. GE Clexane audit2026
  3. CURATIVE small animal2019
  4. Feline enoxaparin PK2014
  5. Feline LMWH crossover2007
  6. Feline ENX+CLO study2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Enoxaparin100 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous, Intravenous
Manufacturer
Sanofi / Aventis Pharma · France
Registration
Georgia Yes, human
In force until 05 May 2028
Human (Ministry of Health, RAMA)
№ რ-041732
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PL044250185, PL044250186, PL044250187, PL207741562
Verified on: 16 Oct 2026
 US Yes, human
№ NDA020164, NDA022138
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Concentration is 100 mg/ml: 4,000 IU is 40 mg in 0.4 ml, not 4,000 mg/ml. Veterinary use is off-label. Dog SC: CURATIVE 0.8 mg/kg q6h. Cat SC: 0.75–1 mg/kg q6–12h, with q6h favoured to reduce peak variability; a separate small study used 1 mg/kg q24h plus clopidogrel for 60 days and must not be generalised. Cat hospital IV protocol: 1 mg/kg bolus then 3 mg/kg/day CRI with clopidogrel in one retrospective cohort. The supplied 40 mg syringe is ungraduated and single-use, so it cannot itself measure most dog/cat partial doses accurately; use a sterile dose-accurate preparation/device process validated by the treating facility.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗